Small molecule · Inhibitor of RAF kinases (pan-Raf) · developed by Novartis Pharmaceuticals
Naporafenib (ERAS-254) is an orally available inhibitor of all members of the Raf serine/threonine kinase family. It binds Raf proteins and blocks Raf-mediated signaling through the Ras/Raf/MEK/ERK pathway, inhibiting proliferation of Raf-overexpressing tumor cells. It is being studied in advanced or metastatic NRAS-mutant melanoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06346067 | Phase 3 | Advanced or Metastatic NRAS-mutant Melanoma | Active not recruiting | ERAS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced or Metastatic NRAS-mutant Melanoma
Updated Nov 15, 2026. Something wrong or missing? Report it on the NVS page.
See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVS catalysts and pipeline →